Efficacy study of CyberKnife stereotactic radiosurgery combined with CIK cell immunotherapy for advanced refractory lung cancer

15Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

CyberKnife (CK), hypofractionated stereotactic radiosurgery, is a preferred option for the treatment of advanced refractory lung cancer which is usually inoperable. Cytokine-induced killer (CIK) cell immunotherapy has a marked radiosensitization effect which aids the elimination of residual tumor cells in distant areas. The main purpose of the present study was to evaluate the clinical efficacy of CK alone and combined with CIK cell therapy for advanced refractory lung cancer. In one year, 22 patients with advanced lung cancer underwent CK therapy at a CyberKnife Center. Of these patients, 11 received CIK cell therapy before or after the CK therapy course. The median prescribed dose in the combined CK and CIK group was 35 Gy (mean, 33.8±5.0 Gy) with a median number of fractions of 5. The median dose for patients who underwent CK alone was 35 Gy (mean, 35.2±6.0 Gy). CIK cell therapy was administered according to the condition of each patient, generally 2 continuous therapeutic sessions in 2 months. The median follow-up period was 3 months. The preliminary curative efficiency rate was 81.82% for patients who underwent CK/CIK and 72.73% for those who received CK alone, according to radiographic re-examination (P>0.05). The median improvement in the Karnofsky scores of the CK/CIK group was 20 (18±10.51) compared with 10 (8.6±11.85) for those who underwent CK alone (P<0.05). The median expression of carcinoembryonic antigen (CEA) before and after treatment was 40.81 and 12.21 ng/ml, respectively, for the CK/CIK group compared with 39.04 and 26.36 ng/ml for CK alone. The median percentage of phenotype expression of the CIK cells (CD3+/CD8+ and CD3+/CD56+) in the patients who underwent CK/CIK was recorded as 64.35% (57.08±16.94%) and 15.27% (18.80±7.00%), respectively, prior to transfusion. The preliminary results of the present study suggest that CK combined with CIK cell immunotherapy improved the short-term outcomes of patients for curative efficacy, Karnofsky scores, tumor marker levels and immune status compared with alternative CK treatments, although further studies are required.

References Powered by Scopus

The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours

3004Citations
N/AReaders
Get full text

Stereotactic body radiation therapy for inoperable early stage lung cancer

2159Citations
N/AReaders
Get full text

Clinical Accuracy of the Respiratory Tumor Tracking System of the CyberKnife: Assessment by Analysis of Log Files

303Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: What we have learned

136Citations
N/AReaders
Get full text

Clinical trials with combination of cytokine-induced killer cells and dendritic cells for cancer therapy

41Citations
N/AReaders
Get full text

Adoptive immunotherapy of Cytokine-induced killer cell therapy in the treatment of Non-small cell lung cancer

36Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Wang, Y. Y., Wang, Y. S., Liu, T., Yang, K., Yang, G. Q., Liu, H. C., … Yang, J. L. (2013). Efficacy study of CyberKnife stereotactic radiosurgery combined with CIK cell immunotherapy for advanced refractory lung cancer. Experimental and Therapeutic Medicine, 5(2), 453–456. https://doi.org/10.3892/etm.2012.818

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

80%

Researcher 1

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

50%

Agricultural and Biological Sciences 1

17%

Pharmacology, Toxicology and Pharmaceut... 1

17%

Chemistry 1

17%

Save time finding and organizing research with Mendeley

Sign up for free